NEW YORK, March 19 – Lynx Therapeutics has signed a collaboration with AstraZeneca to use its MegaType SNP detection technology to discover SNPs associated with asthma, the company said Tuesday.

Under the agreement, AstraZeneca will provide DNA samples from patients with asthma and from a control group, and Lynx of Menlo Park, Calif. will analyze the samples using the MegaType technology. MegaType involves Lynx's proprietary microbeads, which cleave to DNA fragments. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.